Clinical Trial Update: Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating safety and efficacy of Ingenol Mebutate Gel 0.015% for actinic keratosis on the face in solid organ transplant recipients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• Ingenol Mebutate Gel, 0.015% (ingenol mebutate)

Snippet

Sponsor: University of California, San Francisco | Conditions: Actinic Keratosis | Phase 4 | Status: COMPLETED | Results posted: 2019-02-25